For the level of ESMO annual congress, a LBA oral presentation, there is no way any of that foggy looking result package will be accepted.
By Sep, the ORR from part A would be very matured and PFS together with OS profile should be surfacing out.
Most importantly, after the whole oncology field have a good discussion on this Eftilagimod plus PD1 combo, you can imagine how FDA and EMA are thinking on that angle.
Ann: TACTI-003 data selected for oral presentation at ESMO 2024, page-4
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.005(1.41%) |
Mkt cap ! $508.4M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 37.0¢ | 35.0¢ | $906.4K | 2.522M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 71513 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 113290 | 6 |
View Market Depth
| Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |